#BEGIN_DRUGCARD DB04451

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
Not Available

# Chemical_Formula:
C6H12N2O

# Chemical_IUPAC_Name:
4-methylpiperazine-1-carbaldehyde

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
4-Methylpiperazin-1-Yl Carbonyl Group

# HET_ID:
ODS

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C6H12N2O/c1-7-2-4-8(6-9)5-3-7/h6H,2-5H2,1H3

# InChI_Key:
InChIKey=JQTMGOLZSBTZMS-UHFFFAOYSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
4451

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
128.1723

# Molecular_Weight_Mono:
128.094963016

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1EAG

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
-1.2

# Predicted_LogS:
0.74

# Predicted_Water_Solubility:
6.99e+02 g/l

# Primary_Accession_No:
DB04451

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
3269221

# PubChem_Substance_ID:
46508298

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT02419

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CN1CCN(CC1)C=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:23:20 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Secreted protein

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
M83663

# Drug_Target_1_GenBank_ID_Protein:
170841

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
SAP2

# Drug_Target_1_Gene_Sequence:
>1197 bp
ATGTTTTTAAAGAATATTTTCATTGCTCTTGCTATTGCTTTATTAGTCGATGCTACTCCA
ACAACAACCAAAAGATCAGCTGGTTTCGTTGCTTTAGATTTCAGTGTTGTGAAAACTCCT
AAAGCATTCCCAGTTACTAATGGTCAAGAAGGTAAAACTTCCAAAAGACAAGCTGTCCCA
GTGACTTTACACAATGAACAAGTCACTTATGCTGCTGATATTACCGTTGGATCCAATAAT
CAAAAACTTAATGTTATTGTTGATACTGGATCATCTGATTTATGGGTTCCTGATGTTAAT
GTTGATTGTCAAGTCACTTATAGTGATCAAACTGCAGATTTCTGTAAACAAAAGGGGACA
TATGATCCAAGTGGTTCATCAGCTTCACAAGATTTGAATACTCCATTCAAAATTGGTTAT
GGTGATGGATCTTCATCTCAAGGTACTTTATATAAGGATACCGTTGGATTTGGTGGTGTT
TCGATTAAAAATCAAGTTTTAGCTGATGTTGATTCTACTTCAATTGATCAAGGTATTTTA
GGAGTTGGTTATAAAACCAATGAAGCCGGTGGTAGTTATGATAATGTCCCTGTCACTTTA
AAAAAACAAGGAGTCATTGCTAAGAATGCTTATTCACTTTATCTTAATTCTCCAGATGCT
GCCACGGGACAAATAATTTTCGGTGGGGTTGATAATGCTAAATATAGTGGTTCATTAATT
GCATTACCAGTTACTTCTGATCGTGAATTAAGAATTAGTTTGGGTTCAGTTGAAGTTTCT
GGTAAAACCATCAATACTGATAATGTCGATGTTCTTTTGGATTCAGGTACCACCATTACT
TATTTGCAACAAGATCTTGCTGATCAAATCATTAAAGCTTTCAATGGTAAATTAACTCAA
GATTCCAATGGTAATTCATTCTATGAAGTTGATTGTAATTTGTCAGGGGATGTTGTATTC
AATTTTAGTAAAAATGCTAAAATTTCCGTTCCAGCTTCCGAATTTGCTGCTTCTTTACAA
GGTGATGATGGTCAACCATATGATAAATGTCAATTACTTTTCGATGTTAATGATGCTAAC
ATTCTTGGTGATAACTTTTTGAGATCAGCTTATATTGTTTATGATTTGGATGATAATGAA
ATTTCTTTGGCTCAAGTCAAATATACTTCTGCTTCCAGTATTTCTGCCTTGACCTAA

# Drug_Target_1_General_Function:
Involved in aspartic-type endopeptidase activity

# Drug_Target_1_General_References:
1447155	Wright RJ, Carne A, Hieber AD, Lamont IL, Emerson GW, Sullivan PA: A second gene for a secreted aspartate proteinase in Candida albicans. J Bacteriol. 1992 Dec;174(23):7848-53.
1491622	Mukai H, Takeda O, Asada K, Kato I, Murayama SY, Yamaguchi H: cDNA cloning of an aspartic proteinase secreted by Candida albicans. Microbiol Immunol. 1992;36(11):1207-16.
8407785	White TC, Miyasaki SH, Agabian N: Three distinct secreted aspartyl proteinases in Candida albicans. J Bacteriol. 1993 Oct;175(19):6126-33.
8591036	Cutfield SM, Dodson EJ, Anderson BF, Moody PC, Marshall CJ, Sullivan PA, Cutfield JF: The crystal structure of a major secreted aspartic proteinase from Candida albicans in complexes with two inhibitors. Structure. 1995 Nov 15;3(11):1261-71.
9043112	Smolenski G, Sullivan PA, Cutfield SM, Cutfield JF: Analysis of secreted aspartic proteinases from Candida albicans: purification and characterization of individual Sap1, Sap2 and Sap3 isoenzymes. Microbiology. 1997 Feb;143 ( Pt 2):349-56.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
3180

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
42330

# Drug_Target_1_Name:
Candidapepsin-2

# Drug_Target_1_Number_of_Residues:
398

# Drug_Target_1_PDB_ID:
1EAG

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00026	Asp

# Drug_Target_1_Protein_Sequence:
>Candidapepsin-2 precursor
MFLKNIFIALAIALLVDATPTTTKRSAGFVALDFSVVKTPKAFPVTNGQEGKTSKRQAVP
VTLHNEQVTYAADITVGSNNQKLNVIVDTGSSDLWVPDVNVDCQVTYSDQTADFCKQKGT
YDPSGSSASQDLNTPFKIGYGDGSSSQGTLYKDTVGFGGVSIKNQVLADVDSTSIDQGIL
GVGYKTNEAGGSYDNVPVTLKKQGVIAKNAYSLYLNSPDAATGQIIFGGVDNAKYSGSLI
ALPVTSDRELRISLGSVEVSGKTINTDNVDVLLDSGTTITYLQQDLADQIIKAFNGKLTQ
DSNGNSFYEVDCNLSGDVVFNFSKNAKISVPASEFAASLQGDDGQPYDKCQLLFDVNDAN
ILGDNFLRSAYIVYDLDDNEISLAQVKYTSASSISALT

# Drug_Target_1_Reaction:
Preferential cleavage at the carboxyl of hydrophobic amino acids, but fails to cleave Leu15-Tyr, Tyr16-Leu and Phe24-Phe of insulin B chain. Activates trypsinogen, and degrades keratin INHIBITOR Pepstatin

# Drug_Target_1_Signals:
1-18

# Drug_Target_1_Specific_Function:
Preferential cleavage at the carboxyl of hydrophobic amino acids, but fails to cleave 15-Leu-|-Tyr-16, 16- Tyr-|-Leu-17 and 24-Phe-|-Phe-25 of insulin B chain. Activates trypsinogen, and degrades keratin

# Drug_Target_1_SwissProt_ID:
P28871

# Drug_Target_1_SwissProt_Name:
CARP2_CANAL

# Drug_Target_1_Synonyms:
ACP 2
Aspartate protease 2
Candidapepsin-2 precursor
EC 3.4.23.24
Secreted aspartic protease 2

# Drug_Target_1_Theoretical_pI:
4.25

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Lysosome (Potential)

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
CTSL2

# Drug_Target_2_GenBank_ID_Gene:
Y14734

# Drug_Target_2_GenBank_ID_Protein:
3087790

# Drug_Target_2_GeneCard_ID:
CTSL2

# Drug_Target_2_Gene_Name:
CTSL2

# Drug_Target_2_Gene_Sequence:
>1005 bp
ATGAATCTTTCGCTCGTCCTGGCTGCCTTTTGCTTGGGAATAGCCTCCGCTGTTCCAAAA
TTTGACCAAAATTTGGATACAAAGTGGTACCAGTGGAAGGCAACACACAGAAGATTATAT
GGCGCGAATGAAGAAGGATGGAGGAGAGCAGTGTGGGAAAAGAATATGAAAATGATTGAA
CTGCACAATGGGGAATACAGCCAAGGGAAACATGGCTTCACAATGGCCATGAATGCTTTT
CCTGACATGACCAATGAAGAATTCAGGCAGATGATGGGTTGCTTTCGAAACCAGAAATTC
AGGAAGGGGAAAGTGTTCCGTGAGCCTCTGTTTCTTGATCTTCCCAAATCTGTGGATTGG
AGAAAGAAAGGCTACGTGACGCCAGTGAAGAATCAGAAACAGTGTGGTTCTTGTTGGGCT
TTTAGTGCGACTGGTGCTCTTGAAGGACAGATGTTCCGGAAAACTGGGAAACTTGTCTCA
CTGAGCGAGCAGAATCTGGTGGACTGTTCGCGTCCTCAAGGCAATCAGGGCTGCAATGGT
GGCTTCATGGCTAGGGCCTTCCAGTATGTCAAGGAGAACGGAGGCCTGGACTCTGAGGAA
TCCTATCCATATGTAGCAGTGGATGAAATCTGTAAGTACAGACCTGAGAATTCTGTTGCT
AATGACACTGGCTTCACAGTGGTCGCACCTGGAAAGGAGAAGGCCCTGATGAAAGCAGTC
GCAACTGTGGGGCCCATCTCCGTTGCTATGGATGCAGGCCATTCGTCCTTCCAGTTCTAC
AAATCAGGCATTTATTTTGAACCAGACTGCAGCAGCAAAAACCTGGATCATGGTGTTCTG
GTGGTTGGCTACGGCTTTGAAGGAGCAAATTCGAATAACAGCAAGTATTGGCTCGTCAAA
AACAGCTGGGGTCCAGAATGGGGCTCGAATGGCTATGTAAAAATAGCCAAAGACAAGAAC
AACCACTGTGGAATCGCCACAGCAGCCAGCTACCCCAATGTGTGA

# Drug_Target_2_General_Function:
Involved in cysteine-type endopeptidase activity

# Drug_Target_2_General_References:
10029531	Bromme D, Li Z, Barnes M, Mehler E: Human cathepsin V functional expression, tissue distribution, electrostatic surface potential, enzymatic characterization, and chromosomal localization. Biochemistry. 1999 Feb 23;38(8):2377-85.
10382972	Itoh R, Kawamoto S, Adachi W, Kinoshita S, Okubo K: Genomic organization and chromosomal localization of the human cathepsin L2 gene. DNA Res. 1999 Apr 30;6(2):137-40.
11027133	Somoza JR, Zhan H, Bowman KK, Yu L, Mortara KD, Palmer JT, Clark JM, McGrath ME: Crystal structure of human cathepsin V. Biochemistry. 2000 Oct 17;39(41):12543-51.
12975309	Clark HF, Gurney AL, Abaya E, Baker K, Baldwin D, Brush J, Chen J, Chow B, Chui C, Crowley C, Currell B, Deuel B, Dowd P, Eaton D, Foster J, Grimaldi C, Gu Q, Hass PE, Heldens S, Huang A, Kim HS, Klimowski L, Jin Y, Johnson S, Lee J, Lewis L, Liao D, Mark M, Robbie E, Sanchez C, Schoenfeld J, Seshagiri S, Simmons L, Singh J, Smith V, Stinson J, Vagts A, Vandlen R, Watanabe C, Wieand D, Woods K, Xie MH, Yansura D, Yi S, Yu G, Yuan J, Zhang M, Zhang Z, Goddard A, Wood WI, Godowski P, Gray A: The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: a bioinformatics assessment. Genome Res. 2003 Oct;13(10):2265-70. Epub 2003 Sep 15.
9563472	Santamaria I, Velasco G, Cazorla M, Fueyo A, Campo E, Lopez-Otin C: Cathepsin L2, a novel human cysteine proteinase produced by breast and colorectal carcinomas. Cancer Res. 1998 Apr 15;58(8):1624-30.
9727401	Adachi W, Kawamoto S, Ohno I, Nishida K, Kinoshita S, Matsubara K, Okubo K: Isolation and characterization of human cathepsin V: a major proteinase in corneal epithelium. Invest Ophthalmol Vis Sci. 1998 Sep;39(10):1789-96.

# Drug_Target_2_HGNC_ID:
HGNC:2538

# Drug_Target_2_HPRD_ID:
04495

# Drug_Target_2_ID:
3473

# Drug_Target_2_Locus:
9q22.2

# Drug_Target_2_Molecular_Weight:
37330

# Drug_Target_2_Name:
Cathepsin L2

# Drug_Target_2_Number_of_Residues:
334

# Drug_Target_2_PDB_ID:
Not Available

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00112	Peptidase_C1
PF08246	Inhibitor_I29

# Drug_Target_2_Protein_Sequence:
>Cathepsin L2 precursor
MNLSLVLAAFCLGIASAVPKFDQNLDTKWYQWKATHRRLYGANEEGWRRAVWEKNMKMIE
LHNGEYSQGKHGFTMAMNAFGDMTNEEFRQMMGCFRNQKFRKGKVFREPLFLDLPKSVDW
RKKGYVTPVKNQKQCGSCWAFSATGALEGQMFRKTGKLVSLSEQNLVDCSRPQGNQGCNG
GFMARAFQYVKENGGLDSEESYPYVAVDEICKYRPENSVANDTGFTVVAPGKEKALMKAV
ATVGPISVAMDAGHSSFQFYKSGIYFEPDCSSKNLDHGVLVVGYGFEGANSNNSKYWLVK
NSWGPEWGSNGYVKIAKDKNNHCGIATAASYPNV

# Drug_Target_2_Reaction:
The recombinant enzyme hydrolyses proteins (serum albumin, collagen) and synthetic substrates (Z-Phe-Arg-NHMec > Z-Leu-Arg-NHMec > Z-Val-Arg-NHMec)

# Drug_Target_2_Signals:
1-17

# Drug_Target_2_Specific_Function:
Cysteine protease. May have an important role in corneal physiology

# Drug_Target_2_SwissProt_ID:
O60911

# Drug_Target_2_SwissProt_Name:
CATL2_HUMAN

# Drug_Target_2_Synonyms:
Cathepsin L2 precursor
Cathepsin U
Cathepsin V
EC 3.4.22.43

# Drug_Target_2_Theoretical_pI:
9.00

# Drug_Target_2_Transmembrane_Regions:
None

#END_DRUGCARD DB04451
